Desvenlafaxine Succinate Identifies Novel Antagonist Binding Determinants in the Human Norepinephrine Transporter
Authors:
- Darlene C. DeecherDDDarlene C. Deecher
- Rhonda L. RichmondRRRhonda L. Richmond
- Gary StackGSGary Stack
- Paige E. MahaneyPMPaige E. Mahaney
- Eugene TrybulskiETEugene Trybulski
- Richard C. WinnekerRWRichard C. Winneker
- Randy D. BlakelyRBRandy D. Blakely
- 1 November 2007
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 323 (2) , 720-729
Abstract
Desvenlafaxine succinate (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause. Initial evaluation of the pharmacological properties of DVS (J Pharmacol Exp Ther318:657–665, 2006) revealed significantly reduced potency for the hNET expressed in membranes compared with whole cells when competing for [3H]nisoxetine (NIS) binding. Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [3H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3β-(4-iodophenyl)tropane-2β-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine. These differences seem not to arise from preparation-specific perturbations of ligand intrinsic affinity or antagonist-specific surface trafficking but rather from protein conformational alterations that perturb the relationships between distinct hNET binding sites. In an initial search for molecular features that differentially define antagonist binding determinants, we document that Val148 in hNET transmembrane domain 3 selectively disrupts NIS binding but not that of DVS.Keywords
This publication has 39 references indexed in Scilit:
- Desvenlafaxine Succinate: A New Serotonin and Norepinephrine Reuptake InhibitorThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague–Dawley ratsBrain Research, 2006
- The Norepinephrine Transporter in Physiology and Disease2006
- The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitorsEuropean Neuropsychopharmacology, 2005
- Atomoxetine: The First Nonstimulant for The Management of Attention-Deficit/Hyperactivity DisorderAmerican Journal of Health-System Pharmacy, 2004
- Interactions of Tryptamine Derivatives with Serotonin Transporter Species Variants Implicate Transmembrane Domain I in Substrate RecognitionMolecular Pharmacology, 2001
- Cocaine and Antidepressant-Sensitive Biogenic Amine Transporters Exist in Regulated Complexes with Protein Phosphatase 2AJournal of Neuroscience, 2000
- Transmembrane Domain I Contributes to the Permeation Pathway for Serotonin and Ions in the Serotonin TransporterThe Journal of Neuroscience, 1999
- High Affinity Recognition of Serotonin Transporter Antagonists Defined by Species-scanning MutagenesisJournal of Biological Chemistry, 1998
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973